The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Exploiting the tumor microenvironment for B-cell maliganancy treatment
The tumor microenvironment is an important therapeutic consideration. Here, Stephen Devereux, FRCP, FRCPath, PhD, of King’s College Hospital NHS Foundation Trust, London, UK, discusses how cell-cell interactions between malignant cells and healthy cells is pivotal to helping or haltering tumor growth. He describes a practical example, in which therapeutic manipulation of the tumor microenvironment has led to new treatments for chronic lymphocytic leukemia (CLL), in the case of B-cell receptor pathway inhibitors. Prof. Devereux also highlights the key challenge to overcome in this area. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.
